Skip to main content
SpringerLink
Log in

(—)-Deprenyl Combined with L-Dopa in the Treatment of Parkinson’s Disease

  • Chapter
Book cover Inhibitors of Monoamine Oxidase B

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

The fundamental cause of idiopathic Parkinson’s disease (PD) has remained unknown since its original description in the 19th century. Despite this fact, a rational therapeutic approach (exogenous replacement of the missing neurotransmitter, dopamine) was successfully introduced by Cotzias in 1967 [1], following the conceptual framework of Carlsson in 1959 [2], who suggested that dopamine may be a transmitter in the central nervous system involved in the control of motor function and may be involved in the parkinsonian syndrome; and the impressive neurochemical data of Hornykiewicz in 1963 [3] which definitively demonstrated a significant reduction in nigrostriatal dopamine concentration in both idiopathic and postencephalitic Parkinson’s disease. Since then, the major therapeutic efforts have been primarily focused on modifications of the “delivery” of L-dopa [4–8], the use of dopamine agonists [9–12], and, more recently, the use of monoamine oxidase inhibitors, either alone or as adjuvants to levodopa therapy [13–18]. The latter therapeutic approach (specifically the use of a selective MAO-B inhibitor, selegiline (l-deprenyl) in combination with levodopa) is the focus of this review.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. N Engl J Med 1967; 276: 374–379.

    Article  Google Scholar 

  2. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959; 11: 490–493.

    Google Scholar 

  3. Hornykiewicz O. Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-hydroxytryptamin) in der substantia nigra des normalen und parkinsonkranken Menschen. Wien Klin Wschr 1963; 75: 309–312.

    Google Scholar 

  4. Yahr MD, Duvoisin RC, Mendoza MR, Senear MJ, Barrett RE. Modification of L-dopa therapy of parkinsonism by alpha-methyl-dopa hydrazine (MK-486). Trans Am Neurol Asso 1971; 96: 55–58.

    Google Scholar 

  5. Eckstein B, Shaw K, Stern G. Sustained release levodopa in parkinsonism. Lancet 1973; i: 431–432.

    Article  Google Scholar 

  6. Hardie RJ. LeesAJ, Stern GM. On-off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain 1984; 107: 487–506.

    Article  Google Scholar 

  7. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson’s disease: pathogenetic and therapeutic studies. Ann Neurol 1987; 22: 475–479.

    Article  Google Scholar 

  8. Cederbaum JM, Breck L, Kutt H, McDowell FH. Controlled-release levodopa/car-bidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson’s disease. Neurology 1987; 37: 233–241.

    Article  Google Scholar 

  9. Olanow CW, Alberts M J. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson’s disease. Clin Pharmacol 1987; 10: 178–185.

    Google Scholar 

  10. Libman I, Gawd M J, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of “de novo” Parkinson’s disease patients. Can J Neurol Sci 1987; 14: 576–580.

    Google Scholar 

  11. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow-up. Neurology 1987; 37: 826–828.

    Article  Google Scholar 

  12. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 1989; 39: 336–339.

    Article  Google Scholar 

  13. Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303–326.

    Article  Google Scholar 

  14. Riederer P, Przuntek H. MAO-B inhibitor selegiline (R-(-)-deprenyl): a new therapeutic concept in the treatment of Parkinson’s disease. J Neural Transm 1987; [Supplement] 25: 1–197.

    Google Scholar 

  15. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.

    Article  Google Scholar 

  16. Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA, Selegiline use to prevent progression of Parkinson’s disease. Experience in 22 de novo patients. Arch Neurol 1989; 46: 1275–1279.

    Article  Google Scholar 

  17. Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. Selegiline as an adjunct to conventional levodopa therapy in Parkinson’s disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Arch Neurol 1989; 46: 1280–1283.

    Article  Google Scholar 

  18. Elizan TS, Moros DA, Yahr MD. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson’s disease: Experience in 26 patients receiving combined therapy for 26 months. Arch Neurol 1991; 48: 31–34.

    Article  Google Scholar 

  19. Cotzias GC, Papavasilou PS, Gellene R. Modifications of parkinsonism-chronic treatment with L-dopa. New Engl J Med 1969; 280: 337–345.

    Article  Google Scholar 

  20. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343–354.

    Article  Google Scholar 

  21. Marsden CD, Parkes JD. Success and problems of chronic levodopa therapy in Parkinson’s disease. Lancet 1977; i: 345–349.

    Article  Google Scholar 

  22. Yahr MD. Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, editors. Advances in Parkinsonism. Basel: Roche, 1976; pp. 435–444.

    Google Scholar 

  23. Yahr MD. Overview of present day treatment of Parkinson’s disease. J Neural Transm 1978; 43: 227–238.

    Article  Google Scholar 

  24. Yahr MD. Limitations of long-term use of anto-parkinson drugs. Can J Neurol Sci 1984; 2: 191–194.

    Google Scholar 

  25. Zeller AA, Barsky V. In vivo inhibition of liver and brain monoamine oxidase by l-isonicotinyl-2-isopropylhydrazine. Proc Soc Exp Biol Med 1952; 81: 459.

    Article  Google Scholar 

  26. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten Bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wschr 1960; 72: 1236.

    Article  Google Scholar 

  27. Bernheimer V, Birkmayer W, Hornykiewicz O. Verhalten der Monoaminooxydase im Gehrin des Menschen Nach Therapie mit Monoaminooxydase-Hemmern. Wien Klin Wschr 1962; 74: 558–559.

    Google Scholar 

  28. Barbeau A, Duchastel Y. Tranylcypromine and the extrapyramidal syndrome. Can J Psychiat 1962; 7: 91–95.

    Google Scholar 

  29. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963; ii: 849–851.

    Article  Google Scholar 

  30. Horwitz D, Lorenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine and cheese. JAMA 1964; 188: 1108–1110.

    Article  Google Scholar 

  31. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285–1297.

    Article  Google Scholar 

  32. Knoll J, Ecsery Z, Kelemen, K, Nievel J, Knoll B. Phenylisopropyl-methylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965; 155: 154.

    Google Scholar 

  33. Knoll J. Magyar K. Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972; 5: 393–408.

    Google Scholar 

  34. Youdim MBH, Collins GGS, Sandler M, Pare CMB, Bervan Jones AB, Nicolson WJ. Human brain monoamine oxidase: multiple forms and selective inhibition. Nature 1972; 236: 225–228.

    Article  Google Scholar 

  35. Glover V, Sandler M, Owen R, Riley GV. Dopamine is a monoamine oxidase-B substrate in Man. Nature 1977; 265: 80–81.

    Article  Google Scholar 

  36. Sandler M, Glover V, Ashford A, Stern GM. Absence of “cheese effect” during deprenyl therapy: some recent studies. J Neural Transm 1978; 43: 209–215.

    Article  Google Scholar 

  37. Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 1978; 57: 33–38.

    Article  Google Scholar 

  38. Knoll J. The possible mechanisms of action of (—)-deprenyl in Parkinson’s disease. J Neural Transm 1978; 43: 177–198.

    Article  Google Scholar 

  39. Knoll J. Extension of life span of rats by long-term (—)-deprenyl treatment. Mt Sinai J Med 1988; 55: 67–74.

    Google Scholar 

  40. Lees A, Shaw KM, Kohent LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH. Deprenyl in Parkinson’s disease. Lancet 1977; ii: 791–796.

    Article  Google Scholar 

  41. Rinne UK, Siirtola T, Sonninen V. l-Deprenyl treatment of on-off phenomena in Parkinson’s disease. J Neural Transm 1978; 43: 253–262.

    Article  Google Scholar 

  42. Stern GM, Lees AJ, Sandler M, Recent observations on the clinical pharmacology of deprenyl. J Neural Transm 1978; 43: 245–251.

    Article  Google Scholar 

  43. Schacter M, Marsden CD, Parkes JD, Jenner P, Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J Neurol Neurosurg Psychiat 1980; 43: 1016–1021.

    Article  Google Scholar 

  44. Birkmayer W, Knoll J, Riederer P, Youdim MBH. (-)-Deprenyl leads to prolongation of L-dopa efficiency in Parkinson’s disease. Med Probl Pharmacopsychiat 1983; 19: 170–176.

    Google Scholar 

  45. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Morton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a long-term study. J Neural Transm 1985; 64: 113–127.

    Article  Google Scholar 

  46. Heikkila RE, Manzino L, Duvoisin RC, Cabbat FS. Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase inhibitors. Nature 1984; 311: 467–469.

    Article  Google Scholar 

  47. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1984; 106: 209–210.

    Article  Google Scholar 

  48. Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. l-Deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson’s disease: experience in 200 patients. Adv Neurol 1990; 53: 431–435.

    Google Scholar 

  49. Fischer PA, Baas H. Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm 1987; [Supplement] 25: 137–147.

    Google Scholar 

  50. Poewe W, Gerstenbrand F, Ransomayr G. Experience with selegiline in the treatment of Parkinson’s disease. J Neural Transm 1987; [Supplement] 25: 131–135.

    Google Scholar 

  51. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson’s disease. Adv Neurol 1986; 45: 119–125.

    Google Scholar 

  52. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson’s disease. Proc Natl Acad Sci USA 1989; 86: 1398–1400.

    Article  Google Scholar 

  53. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 28: 689–690.

    Article  Google Scholar 

  54. Hauser AR, Olanow CW. Early therapy for Parkinson’s disease (letter to the editor). Arch Neurol 1991; 48: 1009.

    Article  Google Scholar 

  55. Hefti F, Melamed E, Bhawan J, Wurtman RI. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981; 31: 1194–1195.

    Article  Google Scholar 

  56. Melamed E. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson’s disease. Mt Sinai J Med 1988; 55: 35–42.

    Google Scholar 

  57. Brannan T, Martinez-Tica J, Yahr M. Effect of long-term L-dopa administration on striatal extracellular dopamine release. Neurology 1991; 45: 596–598.

    Article  Google Scholar 

Download references

Authors
  1. T. S. Elizan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Pharmacology, ASTA Medica AG, Weismüllerstrasse 45, D-6000, Frankfurt/Main 1, Germany

    I. Szelenyi

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Basel AG

About this chapter

Cite this chapter

Elizan, T.S. (1993). (—)-Deprenyl Combined with L-Dopa in the Treatment of Parkinson’s Disease. In: Szelenyi, I. (eds) Inhibitors of Monoamine Oxidase B. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-6348-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-6348-3_14

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-6349-0

  • Online ISBN: 978-3-0348-6348-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation